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ABSTRACT 
Objective: The aim of the study was to evaluate the effectiveness and safety of Metformin along with Risperidone to prevent antipsychotic-induced 
metabolic syndrome in first-episode schizophrenia patients. 
Methods: This was a randomized, open labelled, prospective study conducted in the Department of psychiatry, Tirunelveli medical college. Around 
96 patients diagnosed with first episode schizophrenia were randomized into 2 groups. Group 1 patients were given T. Risperidone (2 mg twice 
daily, n=48) and group 2 patients were given T. Metformin (500 mg twice daily, n=48) along with T. Risperidone for 6 mo. 
The primary endpoint assessed was the proportion of patients developing metabolic syndrome at the end of 6 mo in both the groups. The secondary 
endpoints were the changes in body mass index (BMI), waist circumference (WC), fasting blood sugar (FBS) and triglycerides (TGL) from baseline to 
the end point. 
Results: There was a significant reduction in BMI and WC at the end of 3 mo (p<0.001) and at the end of 6 mo (p<0.001) when compared to 
baseline in group II individuals. There was a significant reduction in FBS and TGL levels at the end of 6 mo of treatment (p<0.001) in group II 
individuals. There was the significant statistical difference between both the groups (p<0.05) in terms of BMI, WC, FBS, triglycerides. The treatment 
emergent adverse effects with Metformin were generally mild and did not lead to any discontinuation. 
Conclusion: The use of Metformin along with Risperidone may have a better impact on the long-term cardiovascular morbidity and mortality of the 
schizophrenia patients.  
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INTRODUCTION 
Schizophrenia is a debilitating brain disorder characterized by a 
chronic remitting and relapsing course of psychosis that is 
superimposed on persistent "deficit" features such as negative 
symptoms and cognitive dysfunction [1]. It has a worldwide 
prevalence [2] of 1% and is considered the prototype disorder for 
understanding the phenomenology of psychosis [3]. It is associated 
with a high morbidity and mortality resulting from strikingly high 
suicide rate of 10 % [4]. 
The introduction of Chlorpromazine in the late 1950s transformed 
and formed a new frontier in the clinical management of 
Schizophrenia. Initially, "conventional neuroleptics" were 
developed during that era, and they were found to control 
effectively and improve the disease symptomatology but were also 
associated with major drawbacks that include Parkinsonian-like 
movement disorders.  
As a result, of these side effects, newer neuroleptics (termed 
"atypical antipsychotics") were introduced into clinical use [4]. 
Despite the concerns over extrapyramidal side effects and tardive 
dyskinesia are less with these groups of drugs, there has been a 
co-occurrence of atherogenic dyslipidemia with abdominal 
adiposity, impaired fasting glucose, insulin resistance or overt 
Diabetes Mellitus, and Hypertension that constitutes the cluster of 
clinical features known as the Metabolic syndrome [1].  
Risperidone, which comes under the group of atypical 
antipsychotics, is a benzisoxazole derivative [5]. According to 
Clinical Antipsychotic Trials of Intervention Effectiveness study 
(CATIE study), 14% of patients receiving Risperidone had been 
found to have more than 7% increase in weight from baseline [1]. 
Also, a meta-analysis by Allison and coworkers has estimated that the 
mean increases in weight with Risperidone to be 2.1 kg [6]. It has been 
assumed that increased appetite and central Histamine H1
Lifestyle changes are found to be the safe and effective means of 
controlling weight in patients taking these drugs. However, these 
sorts of behavior and dietary modifications are difficult to be 
instituted in subjects with neuropsychiatric disorders [9].  
 antagonism 
along with the alteration of insulin sensitivity and direct impairment of 
metabolic dysregulation might be the underlying cause of weight gain 
[7]. These metabolic derangements not only affect the compliance but 
inevitably also are associated with substantial morbidity (Cardiovascular 
disease, Hypertension, and Diabetes) and mortality [8].  
Metformin, a member of the biguanide class of Oral hypoglycemic 
agents, increases storage of glycogen in skeletal muscles, lower rates 
of production of hepatic glucose, increases the sensitivity of insulin 
thereby reducing blood glucose levels [10]. In view of stemming 
down the metabolic derangements due to atypical antipsychotics 
and also due to the paucity of studies using Metformin along with 
Risperidone in our population, the present study has been designed 
to evaluate the effectiveness and safety of Metformin along with 
Risperidone in preventing antipsychotic-induced Metabolic 
syndrome in first-episode schizophrenia patients. 
MATERIALS AND METHODS 
Ethical consideration 
The study was commenced after getting approval from the 
Institutional Ethical Committee [Ethical committee number: 
309/PHARM/IEC/2013 dated 13/3/2013]. Written informed 
consent was obtained in the local vernacular language from every 
patient (or) his reliable caregiver before enrollment. 
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World health organization (WHO) clinical criteria for metabolic 
syndrome [11]  
Insulin resistance, identified by one of the following 
a) Impaired fasting glucose  
b) Type 2 diabetes 
c) Impaired glucose tolerance 
Plus any two of the following 
a) Plasma triglycerides ≥ 1.7 mmol/l  
b) Antihypertensive medication and/or high blood pressure (≥140 
mm Hg systolic (or) ≥ 90 mm Hg diastolic) 
c) BMI>30 kg/m2
d) Urinary albumin excretion rate ≥ 20 μg/min  (or) albumin: 
creatinine ratio ≥ 3.4 mg/mmol 
 and/(or) waist: hip ratio>0.9 in men,>0.85 in 
women  
e) HDL cholesterol<0.9 mmol/l in men (or)<1.0 mmol/l in women. 
Study design 
Open-labelled, randomized, prospective, comparative, single 
centered, parallel group study.  
Study duration 
Between March 2013-February 2014. 
Study Centre 
Department of Psychiatry, Tirunelveli Medical College Hospital, 
Tirunelveli. 
Sample size 
Total of 96 patients (48 in each group). 
Inclusion criteria 
1. Patients with 18 to 40 y of age who have been diagnosed with first 
episode schizophrenia based on Diagnostic and Statistical Manual of 
Mental disorders (DSM)-IV criteria and on treatment with T. 
Risperidone 2 mg twice a day for ≤ 2 mo. 
Exclusion criteria 
1. Uncooperative and aggressive patients 
2. Patients with suicidal tendency 
3. Pregnant and lactating women 
4. Patients with history of liver disease/renal disease/ cardiovascular 
disease/diabetes mellitus/hypertension/ dyslipidemia/ substance 
abuse/seizure disorder/malignancy 
5. Patients with diagnosis other than schizophrenia  
6. Patients with mental retardation 
7. Patients who are taking other drugs that may affect body weight 
(Carbamazepine, Lithium, and Topiramate, antidepressants, 
Valproate and hormone replacement therapy). 
8. Patients on a special diet and who do exercise for weight loss  
Screening  
Based on the inclusion and exclusion criteria, the subjects were 
enrolled in the study after initial screening. Initial screening at 
baseline included clinical assessment, anthropometric 
measurements like weight, height and waist circumference and 
laboratory investigations like complete blood count, fasting blood 
sugar, serum urea, serum creatinine, liver function tests, routine 
urine analysis and fasting lipid profile. 
Randomization and enrollment  
Subjects who were initiated on T. Risperidone 2 mg orally twice 
daily for ≤ 2 mo for first-episode schizophrenia were randomized 
using computer-generated table into two groups.  
Group 1: Patients were given T. Risperidone 2 mg alone, orally, 
twice daily after food.  
Group 2: Patients were given T. Metformin 500 mg orally, twice 
daily after food along with T. Risperidone. 
T. Risperidone and T. Metformin remained at a fixed dose as 
baseline levels throughout the course of treatment. All subjects were 
under the care of another adult caregiver (or) their parents who 
monitored and recorded drug intake every day to confirm 
adherence. 
Concomitant medications  
Only T. Trihexyphenidyl (5-10 mg/day) for extrapyramidal 
symptoms (or) T. Lorazepam (1-3 mg/day) for insomnia (or) 
agitation were given when needed. 
Compliance  
The compliance in both the group of patients was assessed using a 
pill count. Patients were asked to return the empty strips when they 
come for receiving the drugs. 
Efficacy parameters  
Primary endpoint  
A. The proportion of patients is developing metabolic syndrome at 
the end of 6 mo in both the groups. 
Secondary endpoints  
A. Changes in waist circumference (WC) from baseline to the 
endpoint (after 6 mo of treatment). 
B. Changes in body mass index (BMI) from baseline to the end point.  
C. Changes in fasting blood sugar (FBS) from baseline to the endpoint. 
D. Changes in fasting triglycerides (TGL) from baseline to the endpoint. 
All the above parameters were assessed in the fasting state. Fasting 
was confirmed with patients (or) caregivers at the time of 
assessment. 
Parameter assessment  
Body mass index measurement  
Height  
All subjects were instructed to remove their shoes and socks before 
the procedure. Subjects were instructed to stand on a level floor 
with the feet parallel and pointing forwards. Subjects were asked to 
stand unsupported by not touching the nearby wall (or) furniture. 
Subjects were asked to stand as tall as possible such that the lower 
border of the left orbit and the upper margin of the external auditory 
meatus remain horizontal. Subjects were instructed to breathe out 
gently during the measurement. The measure was placed on the 
subject's head to ensure that the spirit level is balanced. The 
measured height was expressed in centimeters. 
Weight  
The subjects were instructed to remove the shoes, excess clothing, 
and overcoats. Pockets containing keys and wallet were emptied. 
Any heavy jewelry worn by the subject was removed. Weight was 
measured using a manual weighing scale. The weighing scale 
platform was placed on an even floor surface. Before the subject 
stepped onto the platform, it was ensured that the viewfinder 
displayed [0.0] before the measurement. The subjects were 
instructed to stand still on the scale's platform. Subjects were asked 
to stand free without leaning on a chair (or)wall. Subjects were 
instructed to exhale gently during the measurement. The weight was 
measured in kilograms. Once the weight was recorded, the subjects 
were instructed to stand off the platform and re-apply them over 
clothes and shoes. 
BMI calculation  
BMI (or) Quetelet index was calculated using the formula.  
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[Weight (kg)/(height (m)) 2 Follow up visits  ]. BMI was graded as follows.  
Underweight-<18.5 
Normal-18.5 to 25 
Overweight-25 to 30 
Obese->30.  
Waist circumference  
The subjects were instructed about the procedure and permission 
acquired to remove the clothing as it may restrict the accurate 
measurement. A flexible measuring tape was used to measure the 
waist circumference in standing position. It was ensured that the 
tape was neither tight nor loose such that it fits snugly. Subjects 
were instructed to breathe out normally during the measurement, 
and the waist circumference was measured at a point midway 
between the lowest rib and greater trochanter with the subject's 
hands placed loosely by the side. Waist circumference was rounded 
off to nearby whole number and expressed in centimeters. 
Blood investigations  
Patients were previously instructed to come for follow-up visits with 
10 h of fasting. The subjects were made to sit comfortably in a chair 
and informed about the procedure. After sterilizing our hands up to 
the elbows, a tourniquet was placed 3 to 4 inches above the selected 
puncture site neither tight nor too loose in the subjects not longer 
than 1 minute. Then after wearing the non-latex glove, the vein was 
palpated, and the area above it was cleaned, and air dried. The 
subject was asked to make a fist and the arm was firmly grasped to 
make the skin taut, and vein anchored such that at an angle of 15-30 
degrees with the arm surface, the needle was inserted, and 2 ml of 
blood was withdrawn. Blood was collected in a sterilized, dry 
container for further investigation. Using the sample as obtained 
above, fasting blood sugar levels and fasting triglyceride levels were 
assessed using the autoanalyzer. 
Follow-up was done at the end of 3rd and 6th months of starting 
the treatment. Patients were reminded of their follow-up visits by 
a telephone call on the previous day. During the follow-up, 
anthropometric measurements such as weight, height, and waist 
circumference were recorded and fasting blood samples were 
taken to assess the blood sugar and triglycerides. Patients were 
given a diary after enrollment to record the adverse effects, and 
the diary was checked at every follow-up visit. Patients were also 
enquired about the use of concomitant medications through 3 and 
6 mo. 
Statistical analysis  
Statistical analysis was performed with the help of statistical 
package SPSS (Statistical Package for the Social Sciences) version 11.  
1. Baseline characteristics of both the groups were tabulated by 
descriptive statistics (mean, standard deviation) and frequency 
table. They were matched by unpaired student 't' test and Pearson's 
chi-square test. 
2. Between-group analysis was done using unpaired student 't' test 
at baseline, 3 mo and 6 mo.  
3. The student paired 't' test was applied for analysis and 
interpretation within the group at varying intervals as mentioned 
above.  
4. The categorical variable (development of metabolic syndrome) 
between two groups was compared by Chi-square test. 
5. Adverse events were expressed in percentage. 






For a period of one year from March 2013 to February 2014, 
around 112 patients newly diagnosed with schizophrenia were 
initially screened. Based on the inclusion and exclusion criteria, 
around 96 patients were enrolled for the study. They were 
randomly assigned through the computer generated table into 2 
groups receiving either Risperidone alone (or) Metformin along 
with Risperidone. All the patients completed the study, and the 
results were analyzed.  
Baseline characteristics  
Baseline characteristics were similar in both the groups (p>0.05) 
except that the patients in group II had higher BMI levels (p<0.001) 
and larger waist circumference levels (p=0.04) (table 1).  
Primary end point 
According to the WHO criteria for metabolic syndrome [11], it was 
found that 10 patients in group I developed metabolic syndrome and 
1 patient in group II developed metabolic syndrome. The Pearson 
Vishnupriya et al. 
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Chi-Square test was used to test the association between the two 
groups, and the p-value was found to be<0.05 implying a significant 
difference between the groups (table 2). 
Secondary end points 
There was a significant reduction in waist circumference at the end 
of 3 mo (p<0.001) and at the end of 6 mo (p<0.001) when compared 
to baseline with group II individuals (table 3). 
Table 4 shows the statistical difference in waist circumference levels 
between both the groups at the end of 3 mo (p<0.001) and at the 
end of 6 mo (p<0.001). There was a significant reduction in BMI at 
the end of 3 mo when compared to baseline (p<0.001) in group II 
individuals. Also, the BMI reduction at the end of 6 mo with respect 
to baseline was also statistically significant (p<0.001) (table 5). 
There was a significant statistical difference between both the 
groups at the end of 3 mo(p<0.001) and at the end of 6 mo 
(p<0.001) in terms of BMI (table 6). 
Table 7 demonstrates a significant reduction in FBS levels at the end 
of 6 mo of treatment (p<0.001) in group II individuals.  
There was a statistical difference in FBS levels between both the 
groups at the end of 3 mo (p<0.001) and at the end of 6 mo of 
treatment (p<0.001) (table 8).  
Table 9 demonstrates no significant changes in TGL levels at the 
end of 3 mo (p=0. 49) with respect to baseline in Metformin 
group.  
However, there was a significant reduction in TGL levels at the end 
of 6 mo (p<0.001) in group II individuals.  
Table 10 shows a significant rise in TGL levels at the end of 6 mo 
compared to baseline in the group I individuals and similarly 
Metformin along with Risperidone has significantly caused a 
reduction in TGL levels at the end of 6 mo in group II individuals 
signifying the existence of a statistical difference between both the 
groups. 
 
Table 1: Baseline characteristics 
Baseline parameters Group 1 (n=48) Group 2 (n=48) P value 
Age (in yrs) 29.69±5.78 28.75±4.56 0.88 
Gender Male  26 (54) 28 (46) 0.68 
Female 22 (46) 20 (54) 
BMI (Kg/cm 22.61±4.03 2) 26.29±4.57 <0.001
WC (Cms) 
* 
84.48±12.17 89.69±13.25 0.04* 
FBS (Mg%) 90.46±23.47 99.52±30.54 0.1 
TGL (Mg%) 146.42±66.26 164.10±81.64 0.25 
n= Number of patients; 48 patients in each group; Data are expressed as mean values, with plus-minus values as standard deviation (SD), or as 
numbers with percentages in parentheses; P value finds by fishers exact test or by unpaired T-test; *Statistically significant; BMI-Body Mass Index; 
WC-Waist Circumference; FBS-Fasting Blood Sugar.  
 
Table 2: Proportion of patients developing metabolic syndrome at the end of 6 mo in both the groups 
Groups Yes No P value 
Group I 10 38 0.01* 
Group II 1 47 
*Statistically significant. 
 
Table 3: Change in waist circumference in group II patients (Risperidone+Metformin) with respect to baseline 
Time Mean C. I P value 
Baseline 89.7 - - 
End of 3 Months 89 (-0.9 to-0.4) <0.001
End of 6 Months 
* 
87.8 (-2.3 to-1.6) <0.001* 
C. I-Confidence interval; *Statistically significant. 
 
Table 4: Comparison of change in waist circumference from baseline between group I and group II. 
Visits Groups Mean difference from baseline C. I P value 
End of 3 
Months 
Group I 2.50 (2.4 to 4)  
<0.001* Group II -0.67 
End of 6 
Months 
Group I 3.75 (5 to 6.4)  
<0.001Group II * -1.94 
C. I-Confidence interval; *Statistically significant. 
 
Table 5: Change in body mass index in group II patients with respect to baseline 
Time Mean C. I P value 
Baseline 26.3 - - 
End of 3 Months 25.5 (-0.9 to-0.6) <0.001
End of 6 Months 
* 
24.8 (-1.8 to-1.3) <0.001* 
C. I-Confidence interval; *Statistically significant. 
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Table 6: Comparison of change in BMI from baseline between group I and group II 
Visits Groups Mean difference from baseline C. I P value 
End of 3 
Months 
Group 1 0.99 (1.4 to 2)  
<0.001* Group 2 -0.71 
End of 
6 Mo 




C. I-Confidence interval; *Statistically significant. 
 
Table 7: Change in fasting blood sugar levels in group II patients with respect to baseline 
Time Mean C. I P value 
Baseline 99.5 - - 
End of 3 months 102 (-2 to 7.1) 0.28 
End of 6 Months 94 (-10 to-1.3) <0.001* 
C. I-Confidence interval; *Statistically significant. 
 
Table 8: Comparison of change in fasting blood sugar levels from baseline between group I and group II 
Visits Groups Mean difference from baseline C. I P value 
End of 3 mo Group 1 15.81 (6.3 to 20.3) <0.001* 
Group 2 2.52 




C. I-Confidence interval; *Statistically significant. 
 
Table 9: Change in fasting triglyceride levels in group II patients with respect to baseline 
Time Mean C. I P value 
Baseline 164.1 - - 
End of 3 Months 161.5 (-10 to 4.8) 0.49 
End of 6 Months 150.3 (-19.8 to-7.7) <0.001* 
C. I-Confidence interval; *Statistically significant.  
 
Table 10: Comparison of change in fasting triglyceride levels from baseline between group I and group II 
Visits Groups Mean difference from baseline C. I P value 
End of 3 
Months 
Group 1 36.83 (22 to 57.1) <0.001* 
Group 2 -2.58 
End of 6 
Months 




C. I-Confidence interval; *Statistically significant. 
 
Adverse effects  
Metformin was tolerated well by the study participants. The 
treatment emergent adverse effects with Metformin were mainly 
gastrointestinal side effects such as diarrhea and gastritis. They 
were reported by 5% of patients and were transient. It did not lead 
to the discontinuation of the drug. There were no reports suggestive 
of lactic acidosis (or) hypoglycemia.  
DISCUSSION  
Atypical antipsychotics are commonly used for managing 
schizophrenia spectrum disorders nowadays. However, their 
benefit-to-risk ratio is challenged by metabolic abnormalities and 
weight gain [12]. Adherence to medications is difficult and also 
physical interventions may not be possible in psychiatric patients. 
Net weight loss in chronic patients who have undergone 
indeterminate weight gain seems to be more difficult. But weight 
gain mitigation at early stages of treatment seems to be more easy 
and clinically advantageous. Adverse cardiometabolic effects of 
atypical antipsychotics may be minimized by several strategies such 
as a) healthy lifestyle intervention [13], b) switching to lower risk 
antipsychotics [14] and c) the addition of medication that may 
reduce body weight and/(or) lipid and glucose parameters [15].  
Metformin has a well-established safety profile in both adolescents 
and young adults in contrast to the other weight reducing drugs 
which have potentially serious adverse effects. Importantly, 
Metformin is not metabolized by hepatic P450
With regard to the primary endpoint, the development of metabolic 
syndrome was assessed in both the group of patients using the WHO 
criteria [11] for metabolic syndrome. Ten patients (21%) in group I 
and One patient (2%) in group II developed metabolic syndrome, 
thereby implying that Metformin seems to be effective in reducing 
the incidence of metabolic syndrome.  
 enzymes. Hence 
significant drug-drug interactions are not reported. Also, there exist 
no specific interactions with antipsychotic medication [16]. Hence, 
the present study was aimed to evaluate the effectiveness and safety 
of Metformin along with Risperidone in preventing the occurrence 
of antipsychotic-induced metabolic syndrome in first-episode 
schizophrenia patients.  
The secondary endpoints in our study were the individual 
components of metabolic syndrome (Changes in WC, BMI, FBS and 
TGL). Waist circumference has a better correlation with abdominal 
fat and is strongly associated with cardiovascular risk factors when 
compared to other parameters [17]. The increase in waist 
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circumference of every 2 inches is associated with an increase in 
mortality by 17% in men and 13% increase in women.  
Recent studies suggest that the ability of subcutaneous fat depots to 
store excess energy is limited. This results in an "overflow" of excess 
energy to 'ectopic sites' such as skeletal muscle and liver and intra-
abdominal adipose tissue. This excessive ectopic fat eventually leads 
to metabolic dysfunction in organs and so increase in intramuscular 
fat is found to be associated with skeletal muscle insulin resistance 
[18] and an increase in intrahepatic fat is associated with hepatic 
insulin resistance [19]. 
Metformin suppresses appetite and causes satiety through an 
increase in insulin sensitivity and reduction in hyperinsulinemia. 
GLP-1 (uncertain) released from L cells in the intestine via glucose-
dependent insulin secretion lowers blood glucose levels and 
promotes satiety by slowing gastric emptying. In a study by Mannuci 
et al., it was found that the reduced intake of food and weight loss in 
Metformin treated subjects might be related to the increase in GLP-1 
levels [20].  
In our study, within the group, group II showed mean waist 
reduction of (-1.9 cms) from the baseline at the end of 6 mo. This 
implies that the waist circumference reduction by Metformin will 
have a positive impact in preventing metabolic syndrome. 
Waist circumference is a marker of central obesity, whereas BMI is a 
measure of overall adiposity [17]. BMI is strongly associated with 
cardiovascular mortality, which is partially due to the effect of 
obesity on lipoprotein metabolism, blood pressure and insulin 
resistance [21]. However, cardiovascular disease is better predicted 
by BMI coupled together with WC than with the BMI alone [22]. In 
our study, mean baseline BMI value got reduced from 26.29 to 25.5 
at 3 mo and 24.8 at 6 mo of treatment. These results were similar to 
the study conducted in the USA by Morrison et al. which 
demonstrated significant (2.22 kg/m2
As we all know about the microvascular and macrovascular 
complications associated with long-term hyperglycemia, 
normalization of fasting blood sugar levels at the earliest is considered 
wise in the prevention of metabolic syndrome. In our study, fasting 
blood sugar levels did not show any statistical difference at 3 mo of 
treatment (p=0. 28) which was comparable to the results of the study 
by Carrizo et al. that interpreted that Metformin had no significant 
effect on FBS compared with placebo at 14 w of treatment [24]. But in 
our study at 6 mo of treatment, there was a significant reduction in 
FBS (p<0.001). This result was similar to the double-blind, placebo-
controlled study conducted by Baptista et al. showing a significant FBS 
reduction after Metformin addition (p=0. 02) [25]. 
) reduction in BMI with 
Metformin in children taking Risperidone, Olanzapine, Quetiapine 
(or) Valproate [23]. Hence, both BMI and WC play a crucial role in 
the assessment of metabolic syndrome [17] and Metformin along 
with Risperidone has been found to decrease both waist 
circumference and BMI suggests its importance in the prevention of 
metabolic syndrome.  
Elevated triglycerides along with increased waist circumference are 
termed as hypertriglyceridemic waist, which is found to have an 
association with arteriographic cardiovascular disease (CVD) [26]. 
Also, TG elevation is found associated with stroke and MI risk in 
National Health and Nutrition Examination Survey (NHANES)-III 
[27]. Metformin increases AMP-dependent Protein Kinase (AMPK) 
and hormone sensitive lipase activities in brown adipose tissue 
thereby lowering TGL by enhancing uptake of Very Low-Density 
Lipoprotein (VLDL)-TGL, lipolysis of intracellular TGL and 
subsequent fatty acid oxidation by mitochondria [28].  
In our study, fasting triglyceride levels did not differ statistically at 3 
mo when compared to baseline (p=0. 49) in group II individuals. 
However, the mean triglyceride level (164.1 mg%) at baseline 
dropped down (150.3 mg%) at 6 mo, suggesting there was the 
significant statistical difference at 6 mo (p<0.001). This result was 
similar to the study conducted by Shin et al. which showed a 
significant reduction in triglyceride levels after 12 w of treatment 
with Metformin [29]
Thus, our study has shown that Metformin is effective and safe in 
preventing the occurrence of the antipsychotic-induced metabolic 
syndrome in adolescents and young adults with first-episode 
schizophrenia.  
. 
Our study has some Limitations. First, as the duration of study is 
only 6 mo, we do not know whether the improved BMI, WC, FBG and 
TGL levels could be sustained. 
Second, all our study participants were cared by their caregivers 
(or) parents and hence they could have better adherence with 
Metformin when compared to patients living independently with 
schizophrenia. 
Hence, due to the feasibility of Risperidone and Metformin in our 
hospital setting and due to the paucity of trials using both these 
drugs, we conducted this study using Metformin and Risperidone. 
Further studies with more number of patients, long-term follow up 
and Metformin along with lifestyle intervention would provide more 
appealing results regarding the efficacy and safety of Metformin for 
the prevention of antipsychotic-induced metabolic syndrome. 
CONCLUSION  
To conclude, the use of Metformin along with Risperidone was safe 
and effective in the prevention of metabolic syndrome induced by 
atypical antipsychotics. This may have a better impact on the long 
term cardiovascular morbidity and mortality of the schizophrenia 
patients.  
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